- Home
- BREA vs SCNX Comparison
BREA vs SCNX Comparison
Compare BREA & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- SCNX
- Stock Information
- Founded
- BREA 2022
- SCNX 2010
- Country
- BREA Ireland
- SCNX United States
- Employees
- BREA N/A
- SCNX N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- SCNX Other Pharmaceuticals
- Sector
- BREA Consumer Discretionary
- SCNX Health Care
- Exchange
- BREA Nasdaq
- SCNX Nasdaq
- Market Cap
- BREA 13.6M
- SCNX 14.4M
- IPO Year
- BREA 2023
- SCNX 2020
- Fundamental
- Price
- BREA $6.58
- SCNX $1.59
- Analyst Decision
- BREA
- SCNX
- Analyst Count
- BREA 0
- SCNX 0
- Target Price
- BREA N/A
- SCNX N/A
- AVG Volume (30 Days)
- BREA 21.0K
- SCNX 180.9K
- Earning Date
- BREA 01-01-0001
- SCNX 08-10-2025
- Dividend Yield
- BREA N/A
- SCNX N/A
- EPS Growth
- BREA N/A
- SCNX N/A
- EPS
- BREA N/A
- SCNX N/A
- Revenue
- BREA $2,988,009.00
- SCNX $146,901.00
- Revenue This Year
- BREA N/A
- SCNX N/A
- Revenue Next Year
- BREA N/A
- SCNX N/A
- P/E Ratio
- BREA N/A
- SCNX N/A
- Revenue Growth
- BREA 151.51
- SCNX N/A
- 52 Week Low
- BREA $5.00
- SCNX $0.69
- 52 Week High
- BREA $19.50
- SCNX $23.77
- Technical
- Relative Strength Index (RSI)
- BREA 45.35
- SCNX N/A
- Support Level
- BREA $6.06
- SCNX N/A
- Resistance Level
- BREA $8.59
- SCNX N/A
- Average True Range (ATR)
- BREA 0.72
- SCNX 0.00
- MACD
- BREA -0.09
- SCNX 0.00
- Stochastic Oscillator
- BREA 25.14
- SCNX 0.00
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.